receptor sites and drug design

23
Organic Lecture Series 1 Receptor Sites and Drug Design Case Study: Opiates use for Anesthesia & analgesia

Upload: others

Post on 10-May-2022

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Receptor Sites and Drug Design

Organic Lecture Series

1

Receptor Sites and Drug Design

Case Study: Opiates use forAnesthesia & analgesia

Page 2: Receptor Sites and Drug Design

Organic Lecture Series

2

PAIN

Page 3: Receptor Sites and Drug Design

Organic Lecture Series

3

The functional groups and their placement in three-dimensional space determines to a large degree a molecule’s biological activity.

The portion of a molecule that determines the biological effects of a drug is called the pharmacophore.

Medicinal Chemistry

Page 4: Receptor Sites and Drug Design

Organic Lecture Series

4

Medicinal Uses for Morphine:

as an adjunct to general anesthesia

in epidural anesthesia or intrathecal analgesia

for palliative care (i.e. to alleviate pain without

curing the underlying reason for it, usually because

the latter is found impossible)

as an antitussive for severe cough;

(Codeine is better)

Codeine

Medicinal Chemistry

Page 5: Receptor Sites and Drug Design

Organic Lecture Series

5

HO

N CH3

HO

O

Morphine

Codeine(1832)

Oxycodone(1916)

(~1805)

Heroin(1874)

Medicinal Chemistry

Page 6: Receptor Sites and Drug Design

Organic Lecture Series

6

An analgesic (also known as a painkiller) is any member of the group of drugs used to relieve pain (achieve analgesia). The word analgesic derives from Greek an- ("without") and algos ("pain").

A general anesthetic is a drug that brings about a reversible loss or alteration of consciousness.Local anesthesia is any technique to render part of the body insensitive to pain without affecting consciousness.

Medicinal Chemistry

Page 7: Receptor Sites and Drug Design

Organic Lecture Series

7

3

3

3

3

Why do humans have receptor sites for such a complex structure?

Medicinal Chemistry

Page 8: Receptor Sites and Drug Design

Organic Lecture Series

8

Endorphins ("endogenous morphine") are endogenous opioid peptides (discovered in 1974)

An enkephalin is a pentapeptideinvolved in regulating perception of pain in the body

Page 9: Receptor Sites and Drug Design

Organic Lecture Series

9

Opiate antagonist-reversal agentMedicinal Chemistry

Opiate reversal agent (competitive antagonist)-high affinity for μ-receptor site

CH3O

N

O

O

Oxycodone

CH3OH

Page 10: Receptor Sites and Drug Design

Organic Lecture Series

10

Opiate antagonist-reversal agent

Medicinal Chemistry

Opiate reversal agent (blocks “pleasure” centers)-used for treatment of alcohol dependence (alcoholism)& opiate addiction

Page 11: Receptor Sites and Drug Design

Organic Lecture Series

11

33

3

Medicinal Chemistry

Page 12: Receptor Sites and Drug Design

Organic Lecture Series

123

Medicinal Chemistry

Page 13: Receptor Sites and Drug Design

Organic Lecture Series

13

3

2

®

1960-a new opiate, which was based on the piperidinestructure was introduced:

Fentanyl is about 100 X the potency of morphine

Medicinal Chemistry

Page 14: Receptor Sites and Drug Design

Organic Lecture Series

14

3

How does fentanyl and morphine compare?

Medicinal Chemistry

Page 15: Receptor Sites and Drug Design

Organic Lecture Series

15

H2N O

ClPh

BrN O

Ph

K2CO3 NaBH4

NH2

N

NH

PhH O

O O

N

N

PhH

OFentanyl

Commercial Synthesis of Fentanyl Medicinal Chemistry

Page 16: Receptor Sites and Drug Design

Organic Lecture Series

16

N OPh NPh

NH2

KCN HN Ph

CNHCl reflux

NPh

HN Ph

COOH

NPh

HN Ph

CO2Et

EtOH

H3O+

NPh

N Ph

CO2Et

O

Cl

O

NEt3

H2N

NPh

CO2Et

O

H2

Pd(OH)2/C

Anaquest Approach to 4,4-Disubstituted Piperdines:

Page 17: Receptor Sites and Drug Design

Organic Lecture Series

17

H2N

NPh

CO2Et

O

N

N N

N

O

N

N Ph

CO2Et

O

N

N Ph

CO2Et

O

N

N Ph

CO2Et

O

Ph

S

PhBr

K2CO3

Br

K2CO3

BrN

N N

N

O

S

K2CO3

Medicinal Chemistry

Fast acting-less potent than fentanyl

5-10X more potent than fentanyl 10,000 X more potent than morphine

Modify ester-New class of drugs?

Page 18: Receptor Sites and Drug Design

Organic Lecture Series

18

Organic compounds are transformed to molecules of increasing polarity, then excreted by the kidneys:

A

B

C

B’

inactivation

inactivation

Phase I:Oxidation-reductionHydrolysisDemethylation

activation

inactivation

Phase II:Synthesis (acylation, methylationetc.)Conjugation-covalent bonding with carbohydrates, AA or sulfates

Page 19: Receptor Sites and Drug Design

Organic Lecture Series

19

Medicinal ChemistryMetabolism of Metabolism of PiperidinePiperidine AnalgeticsAnalgetics

Page 20: Receptor Sites and Drug Design

Organic Lecture Series

20

N

N Ph

CO2H

O

N

N Ph

O

OHPh

Known to be inactive metabolite

Ph

N

NPh

O

Ph OH

LAH

Cl

O

NEt3

N

N Ph

O

Ph O

O

O Cl

O

R

NEt3

N

N Ph

O

Ph O OR

O

Page 21: Receptor Sites and Drug Design

Organic Lecture Series

21

N

N Ph

O

Ph O OR

O

N

NPh

O

Ph O

O

Medicinal Chemistry

Pharmacological Profile:Pharmacological Profile:MHP: ED50=0.06 potent analgetic

MHP: >15 min—long acting analgetic

Ki = 3-9 (strength of μ receptor binding)

Anesthesia—2-3 Minutes-short acting

Page 22: Receptor Sites and Drug Design

Organic Lecture Series

22

Esters & Carbonates

Medicinal Chemistry

Page 23: Receptor Sites and Drug Design

Organic Lecture Series

23

Remifentanil is a specific μ-receptor agonist. It is potent & short acting- (1/2 life~4 min)•a reduction in sympathetic nervous system tone, •Slight respiratory depression and analgesia. •dose-dependent decrease in heart rate arterial pressure•respiratory rate and tidal volume near normal

Ultra short acting analgesic